Alkermes Appoints Joshua Reed as Chief Financial Officer
Alkermes plc (Nasdaq: ALKS) is excited to announce the newest addition to its leadership team with the appointment of Joshua Reed as Chief Financial Officer (CFO). This key decision reflects a strategic move to enhance the company’s financial operations while advancing its innovative initiatives.
Experience and Vision for Alkermes
With over three decades of financial expertise focused primarily in the biotechnology and pharmaceutical sectors, Joshua Reed brings a wealth of knowledge to Alkermes. His prior role as CFO for Omega Therapeutics marks a significant achievement in his career, where he excelled in financial management for a publicly-traded biotechnology company. Additionally, Reed served at Aldeyra Therapeutics before that, gaining valuable experiences that enhance his qualification for the role at Alkermes.
Strong Background in the Industry
Before joining Alkermes, Reed contributed significantly at Bristol Myers Squibb, where he held the position of Vice President and Head of Finance Operations in the U.S. and Puerto Rico. He has also cultivated financial expertise through roles at prominent financial institutions, including JPMorgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank.
Looking Forward to Future Growth
Commenting on his new role, Joshua Reed expressed enthusiasm, stating, "I am delighted to be joining Alkermes and look forward to collaborating with Richard and the team. Together, we aim to build upon Alkermes' strong financial foundation and align our financial strategy with the company's goals for operational excellence and innovative growth." This spirit of collaboration is crucial as Alkermes finds itself at pivotal moments in its evolution.
Commitment to Delivering Shareholder Value
Richard Pops, Chief Executive Officer of Alkermes, welcomed Joshua Reed during this exciting chapter for the company. He emphasized the importance of Reed’s extensive financial background and his dedication to excellence, stating, "His financial acumen will play a pivotal role in advancing our pipeline and enhancing performance across our commercial operations. We are committed to maximizing long-term shareholder value, and I am confident Joshua will have a significant positive impact on our organization.
A Vision for Innovative Medicines
Alkermes plc, a mid-cap growth and value equity company listed on Nasdaq under the ticker ALKS, is dedicated to developing innovative biopharmaceutical solutions, particularly in neuroscience. Their proprietary commercial products target severe conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder. With a varied portfolio, the company is advancing numerous clinical and preclinical candidates aimed at treating neurological disorders like narcolepsy and idiopathic hypersomnia.
Headquartered in Ireland, Alkermes maintains a robust presence with facilities for research and development located in Massachusetts, alongside a manufacturing plant situated in Ohio. The company continues to prioritize designing and implementing groundbreaking therapies that respond to complex medical needs.
Connecting with Alkermes
As Alkermes moves ahead, the company remains accessible for inquiries regarding investment and media relations. For investors, they offer a direct line through Sandy Coombs at +1 781 609 6377, while media inquiries can be directed to Katie Joyce at +1 781 249 8927. This commitment to transparency ensures that stakeholders are well-informed about upcoming advancements and initiatives.
Frequently Asked Questions
Who is Joshua Reed?
Joshua Reed is the newly appointed Chief Financial Officer of Alkermes plc, bringing over 30 years of financial leadership experience in biotechnology.
What are Joshua Reed's past roles?
Before joining Alkermes, Reed served as CFO of Omega Therapeutics and Aldeyra Therapeutics, among other significant positions at major institutions.
What is the focus of Alkermes plc?
Alkermes is a biopharmaceutical company focused on developing innovative medicines in the neuroscience field, particularly for psychiatric and neurological conditions.
How can investors contact Alkermes?
Investors can reach out to Sandy Coombs at +1 781 609 6377 for any inquiries regarding investments in Alkermes.
What is the mission of Alkermes?
The mission of Alkermes is to deliver transformative medicines for complex diseases, ensuring that they meet the diverse needs of patients and enhance health outcomes.
